Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at Leerink Partners Global Healthcare Conference Transcript

Feb 27, 2019 / 02:00PM GMT
Release Date Price: $92.33
Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - MD of Rare Diseases & Senior Analyst

Good morning. Welcome to the BioMarin fireside chat. It's my pleasure to get us started. I'm Joe Schwartz from biotech research team at SVB Leerink, and I'm pleased to be joined by BioMarin's Senior Vice President and CMO, Geoff Nichol. And a very exciting time for BioMarin on a number of fronts. Geoff's going to start us off with some slides, and then we'll go into Q&A. If you have anything you'd like to ask, just raise your hand and we'll address that. Thank you, Geoff.

Geoffrey M. Nichol
BioMarin Pharmaceutical Inc. - Senior VP, Chief Medical Officer & Head of Global Clinical Development

Okay. Thank you very much for the opportunity to present on behalf of BioMarin.

Why is it not advancing? Not going, I'm afraid.

Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - MD of Rare Diseases & Senior Analyst

Can we get the slides to advance? There we go.

Let's try again. Thank

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot